Stock Analysis
Ascendis Pharma A/SASND
Sector: Healthcare · Industry: Biotechnology
AnalystsStrong Buy28 analystsPrice is 36% of the way from the year's low to its high.
PMP Verdict
Insufficient financial data
No financial statements on file for this ticker — fundamental scores are not computed.
Bull Case
- ✓ROE 86.9% — efficient capital deployment
What's happening with ASND
Risk Flags
- ⚠Interest coverage -1.8× — thin debt cushion
About Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. Show more
The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Employees: 1,189 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
Valuation
35DP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF36.0xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.8%C
Grade C: LowInverse of Finnhub P/FCF (own TTM FCF unavailable)
P/S (TTM)12.06xD
Grade D: ExpensivePrice / TTM Revenue (own statements)
EV/EBITDA42.7xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales11.7xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E19.1xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio10.96xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.43A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
50CROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE86.9%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA44.0%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin70.8%A
Grade A: HighNet Income / Revenue
Operating Margin—
TTM EBIT / TTM Revenue
Gross Margin91.3%A
Grade A: PremiumGross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Financial Health
25EAltman Z-Score—
Bankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.99xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.23xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-1.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.31xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
0EPiotroski F-Score—
Financial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability—
EBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.62xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Bodenhoff Mads Filed | Bodenhoff Mads | Option exercise | -3000 | |
Bodenhoff Mads Filed | Bodenhoff Mads | SellOpen market sale | -3000 | |
Bodenhoff Mads Filed | Bodenhoff Mads | Option exercise | +3.0K | |
HOLTUG LARS Filed | HOLTUG LARS | SellOpen market sale | -236 | |
BIENAIME JEAN JACQUES Filed | BIENAIME JEAN JACQUES | BuyOpen market buy | +900 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
BIENAIME JEAN JACQUES Filed | BIENAIME JEAN JACQUES | BuyOpen market buy | +1.1K | |
SMITH SCOTT THOMAS Filed | SMITH SCOTT THOMAS | BuyOpen market buy | +100 | |
SMITH SCOTT THOMAS Filed | SMITH SCOTT THOMAS | BuyOpen market buy | +250 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years—
Share of completed fiscal years with positive free cash flow
Net Margin Floor—
Weakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$12.27
Cash & short-term investments per share (Finnhub)
Book Value / Share$21.70
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.—
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity—
Shareholders' equity (book value)
Asset / Liability—
Total Assets / Total Liabilities
Market
Market Cap$14.82B
Current Market Capitalization
Beta0.39B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Ratio snapshot Oct 16, 2026
Key Insights: Ascendis Pharma A/S (ASND)
ASND is down 0.60% at the last close.
- Return on equity of 86.9% is well above the market average.
See how ASND ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ASND moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 23 | Regular | 221.69 | -6.69% | -2.19 |
Frequently Asked Questions about ASND
What is the current Ascendis Pharma A/S (ASND) stock price?
ASND is trading at $225.25 at the last market close, down 0.60% on the session. PreMarketPrice tracks ASND pre-market, intraday and after-hours prices.
Is ASND stock a buy right now?
PreMarketPrice's quantitative model rates Ascendis Pharma A/S's financial health at 25/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ASND stock overvalued?
Ascendis Pharma A/S trades at a trailing P/E of n/a and our valuation score rates it 35/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Ascendis Pharma A/S report earnings?
No confirmed earnings date is currently scheduled for ASND. The Earnings section lists recent reports and updates as dates are announced.
What sector does Ascendis Pharma A/S operate in?
Ascendis Pharma A/S operates in the Healthcare sector, within the Biotechnology industry. The Related Stocks section lists sector peers for comparison.
What does Ascendis Pharma A/S do?
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients.
About Ascendis Pharma A/S (ASND) Stock
Ascendis Pharma A/S (ASND) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry. As of the latest update, Ascendis Pharma A/S is trading at $225.25, down 0.60% on the day with a market capitalization of $14.8 billion. The financial health score for ASND is 25/100, which indicates poor financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ASND stock.
ASND Stock Analysis & Key Metrics
On PreMarketPrice, you can track Ascendis Pharma A/S (ASND) across multiple dimensions:
- Pre-market price & movement: Real-time ASND stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ASND with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Ascendis Pharma A/S across multiple reporting periods.
- Financial health score: A composite score of 25/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ASND.
- Sector peers: Compare ASND against 4 other healthcare stocks on key financial metrics.
Is ASND a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Ascendis Pharma A/S (ASND) as an investment. The financial health score of 25/100 suggests poor financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Ascendis Pharma A/S (ASND) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.